Raptor Group — 2017 Investments
1 investments dated 2017 · listed companies and verified rows first · show all
Concarloconcarlo.comin𝕏Mar 2017
Concarlo Therapeutics develops cancer therapeutics that target CDK4/6-driven cell proliferation and CDK2-driven resistance, focusing on improving outcomes for cancer patients through novel approaches in p27 biology.
BiotechBrooklyn, US
Stacy Blain(Founder and CEO)LisaMarie Casey(President and Manager)
PartnerJames J. Pallotta· solo GP
Co-investorsBioAdvanceCreative Destruction Lab (CDL)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.